Consistent with observations from other pathologies, GPX3 has also been shown to diminish fibrosis in conditions such as hepatocellular carcinoma invasiveness [7] and is emerging as a potential therapeutic target for treating fibrosis associated with interstitial lung disease, chronic kidney disease and various cardiac disorders [10, 39, 40, 41]. This evidence concerns the gene GPX3 and chronic kidney disease.